Cargando…

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis

Tuberous sclerosis complex (TSC) is a genetic multisystem disorder that results from mutations in the TSC1 or TSC2 genes, and is associated with hamartomas in several organs, including subependymal giant cell tumors. The neurological manifestations of TSC are particularly challenging and include inf...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kim, Won Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Pediatric Society 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174359/ https://www.ncbi.nlm.nih.gov/pubmed/21949518 http://dx.doi.org/10.3345/kjp.2011.54.6.241

Ejemplares similares

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
por: YANG, GUANG, et al.
Publicado: (2015)

New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012)

Radiological Characteristics of Renal Lesions During Tuberous Sclerosis Complex: Impact of Mechanistic Target of Rapamycin Inhibitor Treatment
por: Pfirmann, Pierre, et al.
Publicado: (2022)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
por: Groenewoud, Marlous J., et al.
Publicado: (2013)

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
por: Lin, Yu-Ting, et al.
Publicado: (2022)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
por: Chan, Jung-Yi Lisa, et al.
Publicado: (2014)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

Mammalian target of rapamycin and head and neck squamous cell carcinoma
por: Liao, Yu-Min, et al.
Publicado: (2011)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
por: Yan, Junfang, et al.
Publicado: (2021)

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Electroacupuncture induces weight loss by regulating tuberous sclerosis complex 1-mammalian target of rapamycin methylation and hypothalamic autophagy in high-fat diet-induced obese rats
por: Yao, Junpeng, et al.
Publicado: (2022)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
por: Hasbal, Nuri Baris, et al.
Publicado: (2021)

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials
por: Paluri, Ravi K., et al.
Publicado: (2019)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Driving neural regeneration through the mammalian target of rapamycin
por: Maiese, Kenneth
Publicado: (2014)

Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders
por: Chong, Zhao Zhong, et al.
Publicado: (2010)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
por: Yoon, Mee-Sup
Publicado: (2017)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
por: Lawrence, Jessica, et al.
Publicado: (2018)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
por: Mao, Shanshan, et al.
Publicado: (2017)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Mammalian Tribbles Homologs at the Crossroads of Endoplasmic Reticulum Stress and Mammalian Target of Rapamycin Pathways
por: Cunard, Robyn
Publicado: (2013)

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_f56p8c998p163o2iglvpavjh1t